Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008

American Journal of Medicine

Volumn 122, Issue 1 SUPPL., 2009, Pages

  Lewis, Sandra J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Hypercholesterolemia; Risk factor; Statin; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIET SUPPLEMENTATION; DOCTOR PATIENT RELATION; DYSLIPIDEMIA; FAMILY HISTORY; FLUSHING; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH PROMOTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PATIENT ASSESSMENT; PATIENT COUNSELING; PATIENT EDUCATION; PERIODIC MEDICAL EXAMINATION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EICOSAPENTAENOIC ACID; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TRIGLYCERIDES;

EID: 57749093662     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.10.016     Document Type: Article

References (53)

1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update (2005), American Heart Association, Dallas, TX
2. Insull Jr. W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 122 suppl (2008) S3-S14
3. Berenson G.S., and Pickoff A.S. Preventive cardiology and its potential influence on the early natural history of adult heart disease: the Bogalusa Heart Study and the Heart Smart Program. Am J Med Sci 310 suppl 1 (1995) S133-S138
4. La Rosa J.C., and Brown C.D. Cardiovascular risk factors in minorities. Am J Med 118 (2005) 1314-1322
5. Bays H.E. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 122 suppl (2008) S26-S37
6. National Cholesterol Education Program. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106 (2002) 3143-3421
7. O'Keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146
8. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (1992) 525-584
9. McCrindle B.W., Urbina E.M., Dennison B.A., et al., American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, the American Heart Association Council on Cardiovascular Disease in the Young, and the American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council on Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115 (2007) 1948-1967
10. Nasir K., Budoff M.J., Wong N.D., et al. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 116 (2007) 619-626
11. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
12. Schwandt P. The importance of reaching lipid targets: statins and the prevention of atherosclerosis. Int J Clin Pract 57 (2003) 396-404
13. Jacobson T.A., Gutkin S.W., and Harger C.R. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Curr Med Res Opin 22 (2006) 1065-1073
14. Grundy S.M., Cleeman J.I., Merz C.N.B., et al., National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
16. Chobanian A.V., Bakris G.L., Black H.R., et al., National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute. NIH Publication No. 04-5230, August 2004. www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf Accessed April 23, 2007
17. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
18. Hsia J., Margolis K.L., Eaton C.B., et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115 (2007) 855-860
19. Braun L.T. Cardiovascular disease: strategies for risk assessment and modification. J Cardiovasc Nurs 21 suppl 1 (2006) S20-S42
20. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 1 (2008) S12-S54
21. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association and National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
22. Deedwania P., Barter P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
23. Ridker P.M., Danielson E., Fonseca F.A.H., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
24. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global CV risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
25. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 364 (2004) 685-696
26. Lescol [prescribing information] (2006), Novartis Pharmaceuticals Corporation, East Hanover, NJ October
27. Mevacor [prescribing information] (2007), Merck & Co., Inc, Whitehouse Station, NJ December
28. Niacor [package insert] (2003), Upsher-Smith Laboratories, Inc, Minneapolis, MN June
29. Pravachol [prescribing information] (2007), Bristol-Myers Squibb, Princeton, NJ March
30. Crestor [prescribing information] (2007), AstraZeneca Pharmaceuticals LP, Wilmington, DE November
31. Lipitor [prescribing information] (2007), Parke-Davis, New York, NY November
32. Zocor [package insert] (2007), Merck & Co., Inc, Whitehouse Station, NJ November
33. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 92 (2003) 152-160
34. McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., and Blasetto J.W. Comparison of the efficacy of rosuvastatin versus atorvastatin, simavastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 19 (2003) 689-698
35. Gotto Jr. A.M. Establishing the benefit of statins in low-to-moderate risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Atheroscler Suppl 8 (2007) 3-8
36. Clearfield M., Downs J.R., Lee M., Langendorfer A., McConathy W., and Gotto Jr. A.M. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 96 (2005) 1674-1680
37. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 suppl (2006) 89C-94C
38. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 suppl 8A (2006) 77C-81C
39. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
40. Mangoni A.A., and Jackson S.H. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol 61 (2006) 494-501
41. Ali R., and Alexander K.P. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 5 (2007) 52-63
42. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA 285 (2001) 1711-1718
43. Feldman T., Koren M., Insull Jr. W., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 93 (2004) 1481-1486
44. Ballantyne C.M., Weiss R., Moccetti T., et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99 (2007) 673-680
45. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
46. Covington M.B. Omega-3 fatty acids. Am Fam Physician 70 (2004) 133-140
47. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098
48. Chagan L., Ioselovich A., Asherova L., and Cheng J.W. Use of alternative pharmacotherapy in management of cardiovascular diseases. Am J Manag Care 8 (2002) 270-285
49. Katan M.B., Grundy S.M., Jones P., Law M., Miettinen T., Paoletti R., and Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 78 (2003) 965-978
50. Lee I.M., Cook N.R., Baziano J.M., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized, controlled clinical trial. JAMA 294 (2005) 56-65
51. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007) 842-857
52. Gardner C.D., Lawson L.D., Block E., Chatterjee L.M., Kiazand A., Balise R.R., and Kraemer H.C. Effect of raw garlic vs. commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 167 (2007) 346-353
53. Levy H.B., and Kohlhaas H.K. Consideration for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother 40 (2006) 290-294